<h3>关键洞察</h3>
<ul>
<li>个人投资者在 Corvus Pharmaceuticals 的大量持股表明，他们在管理和商业战略上有更大的发言权</li>
<li>前 12 大股东持有公司 51% 的股份</li>
<li>Corvus Pharmaceuticals 的机构持股比例为 37%</li>
</ul>
<p>特朗普承诺要 &#34;释放&#34; 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>要了解谁真正控制着 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)，了解公司的所有权结构至关重要。而持有最大份额的群体是个人投资者，拥有 40% 的股份。换句话说，这个群体在对公司的投资中将获得最多的收益（或承受最多的损失）。</p>
<p>在上周股价上涨 12% 后，个人投资者获利最多，但持有 37% 股票的机构投资者也从中受益。</p>
<p>让我们深入探讨 Corvus Pharmaceuticals 各类股东的情况，从下面的图表开始。</p>
<p>查看我们对 Corvus Pharmaceuticals 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-ownership-breakdown-1-dark-2/1758795234183?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-ownership-breakdown-1-dark-2/1758795234183"/></p>
<p>NasdaqGM:CRVS 所有权结构 2025 年 9 月 25 日</p>
<h2>机构持股对 Corvus Pharmaceuticals 的启示是什么？</h2>
<p>机构投资者通常将自己的回报与一个常见的基准指数的回报进行比较。因此，他们通常会考虑购买包含在相关基准指数中的大型公司。</p>
<p>我们可以看到 Corvus Pharmaceuticals 确实有机构投资者，他们持有公司相当一部分的股票。这意味着为这些机构工作的分析师已经关注了这只股票，并且他们对其表示认可。但和其他人一样，他们也可能会出错。如果两家大型机构投资者同时试图抛售一只股票，股价大幅下跌并不罕见。因此，查看 Corvus Pharmaceuticals 过去的盈利轨迹是值得的（见下文）。当然，还要记住还有其他因素需要考虑。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-earnings-and-revenue-growth-1-dark-2/1758795236591?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-earnings-and-revenue-growth-1-dark-2/1758795236591"/></p>
<p>NasdaqGM:CRVS 盈利和收入增长 2025 年 9 月 25 日</p>
<p>我们的数据显示对冲基金持有 Corvus Pharmaceuticals 9.5% 的股份。这一点值得注意，因为对冲基金通常是相当活跃的投资者，可能会试图影响管理层。许多人希望在短期或中期内看到价值创造（和更高的股价）。根据我们的数据，我们可以看到最大股东是 OrbiMed Advisors LLC，持有 9.6% 的流通股。作为对比，第二大股东持有约 9.5% 的流通股，第三大股东持有 5.7%。此外，首席执行官 Richard Miller 拥有公司 3.1% 的股份。</p>
<p>更仔细地查看我们的所有权数据表明，前 12 大股东的合计持股比例为 51%，这意味着没有单一股东拥有多数股份。</p>
<p>虽然研究一家公司的机构持股可以为您的研究增值，但研究分析师的推荐也是一个好习惯，以更深入地了解股票的预期表现。有相当数量的分析师覆盖这只股票，因此了解他们对未来的整体看法可能会很有用。</p>
<h2>Corvus Pharmaceuticals 的内部持股</h2>
<p>虽然内部人的确切定义可能是主观的，但几乎所有人都认为董事会成员是内部人。公司管理层向董事会负责，而董事会应代表股东的利益。值得注意的是，有时高层管理人员本身也在董事会中。</p>
<p>大多数人认为内部持股是积极的，因为它可以表明董事会与其他股东的利益一致。然而，有时过多的权力集中在这个群体中。</p>
<p>我们可以报告，内部人确实持有 Corvus Pharmaceuticals, Inc. 的股份。作为个人，内部人共同持有价值 1800 万美元的公司股份，总市值为 4.56 亿美元。看到内部人进行一些投资是件好事，但可能值得检查这些内部人是否在增持。</p>
<h2>公众持股</h2>
<p>公众持有 40% 的股份，主要由个人投资者组成，对 Corvus Pharmaceuticals 有一定的影响力。虽然这种持股规模可能不足以在政策决策中影响他们的利益，但他们仍然可以对公司政策产生集体影响。</p>
<h2>私募股权持股</h2>
<p>私募股权公司持有 Corvus Pharmaceuticals 9.6% 的股份。这表明他们在关键政策决策中可能具有影响力。有时我们看到私募股权公司会长期持有，但一般来说，他们的投资周期较短，正如其名所示，他们不太会投资于上市公司。经过一段时间，他们可能会考虑出售并将资本重新部署到其他地方。</p>
<h2>下一步：</h2>
<p>考虑拥有公司股份的不同群体总是值得的。但要更好地理解 Corvus Pharmaceuticals，我们需要考虑许多其他因素。例如，风险 - Corvus Pharmaceuticals 有 <strong>3 个警告信号</strong>（其中 1 个是显著的），我们认为您应该了解。</p>
<p>但最终 <strong>未来</strong> 而不是过去，将决定这家公司的所有者将如何表现。因此，我们认为查看这份免费的报告是明智的，该报告显示分析师是否预测更光明的未来。</p>
<p>注意：本文中的数据是根据过去 12 个月的数据计算得出的，指的是财务报表日期所在月份的最后一天结束的 12 个月期间。这可能与全年年报数据不一致。</p>

Corvus制药

<p>Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS）上周股价上涨了 12%，使个人和机构投资者均受益。个人投资者持有公司 40% 的股份，给予他们对管理和战略的显著影响力，而机构投资者则拥有 37% 的股份。前 12 大股东合计持有 51% 的股份，表明没有单一的多数股东。对冲基金持有 9.5% 的股份，内部人士持有价值 1800 万美元的股份。公众持有 40% 的股份，使其在公司政策上具有一定的影响力，而私募股权公司持有 9.6% 的股份，暗示在关键决策中可能具有影响力</p>

<h3>Key Insights</h3>
<div class="lb-trans"><h3>关键洞察</h3>
</div><ul>
<li>The considerable ownership by individual investors in Corvus Pharmaceuticals indicates that they collectively have a greater say in management and business strategy</li>
<li>51% of the business is held by the top 12 shareholders</li>
<li>Institutional ownership in Corvus Pharmaceuticals is 37%</li>
</ul>
<div class="lb-trans"><ul>
<li>个人投资者在 Corvus Pharmaceuticals 的大量持股表明，他们在管理和商业战略上有更大的发言权</li>
<li>前 12 大股东持有公司 51% 的股份</li>
<li>Corvus Pharmaceuticals 的机构持股比例为 37%</li>
</ul>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要 &#34;释放&#34; 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>To get a sense of who is truly in control of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual investors with 40% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.</p>
<div class="lb-trans"><p>要了解谁真正控制着 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)，了解公司的所有权结构至关重要。而持有最大份额的群体是个人投资者，拥有 40% 的股份。换句话说，这个群体在对公司的投资中将获得最多的收益（或承受最多的损失）。</p>
</div><p>Following a 12% increase in the stock price last week, individual investors profited the most, but institutions who own 37% stock also stood to gain from the increase.</p>
<div class="lb-trans"><p>在上周股价上涨 12% 后，个人投资者获利最多，但持有 37% 股票的机构投资者也从中受益。</p>
</div><p>Let's delve deeper into each type of owner of Corvus Pharmaceuticals, beginning with the chart below.</p>
<div class="lb-trans"><p>让我们深入探讨 Corvus Pharmaceuticals 各类股东的情况，从下面的图表开始。</p>
</div><p>View our latest analysis for Corvus Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对 Corvus Pharmaceuticals 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-ownership-breakdown-1-dark-2/1758795234183" alt="" original-src="https://images.simplywall.st/asset/chart/279359732-ownership-breakdown-1-dark-2/1758795234183"/></p>
<p>NasdaqGM:CRVS Ownership Breakdown September 25th 2025</p>
<div class="lb-trans"><p>NasdaqGM:CRVS 所有权结构 2025 年 9 月 25 日</p>
</div><h2>What Does The Institutional Ownership Tell Us About Corvus Pharmaceuticals?</h2>
<div class="lb-trans"><h2>机构持股对 Corvus Pharmaceuticals 的启示是什么？</h2>
</div><p>Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.</p>
<div class="lb-trans"><p>机构投资者通常将自己的回报与一个常见的基准指数的回报进行比较。因此，他们通常会考虑购买包含在相关基准指数中的大型公司。</p>
</div><p>We can see that Corvus Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Corvus Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.</p>
<div class="lb-trans"><p>我们可以看到 Corvus Pharmaceuticals 确实有机构投资者，他们持有公司相当一部分的股票。这意味着为这些机构工作的分析师已经关注了这只股票，并且他们对其表示认可。但和其他人一样，他们也可能会出错。如果两家大型机构投资者同时试图抛售一只股票，股价大幅下跌并不罕见。因此，查看 Corvus Pharmaceuticals 过去的盈利轨迹是值得的（见下文）。当然，还要记住还有其他因素需要考虑。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-earnings-and-revenue-growth-1-dark-2/1758795236591" alt="" original-src="https://images.simplywall.st/asset/chart/279359732-earnings-and-revenue-growth-1-dark-2/1758795236591"/></p>
<p>NasdaqGM:CRVS Earnings and Revenue Growth September 25th 2025</p>
<div class="lb-trans"><p>NasdaqGM:CRVS 盈利和收入增长 2025 年 9 月 25 日</p>
</div><p>Our data indicates that hedge funds own 9.5% of Corvus Pharmaceuticals. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Looking at our data, we can see that the largest shareholder is OrbiMed Advisors LLC with 9.6% of shares outstanding. For context, the second largest shareholder holds about 9.5% of the shares outstanding, followed by an ownership of 5.7% by the third-largest shareholder. Furthermore, CEO Richard Miller is the owner of 3.1% of the company's shares.</p>
<div class="lb-trans"><p>我们的数据显示对冲基金持有 Corvus Pharmaceuticals 9.5% 的股份。这一点值得注意，因为对冲基金通常是相当活跃的投资者，可能会试图影响管理层。许多人希望在短期或中期内看到价值创造（和更高的股价）。根据我们的数据，我们可以看到最大股东是 OrbiMed Advisors LLC，持有 9.6% 的流通股。作为对比，第二大股东持有约 9.5% 的流通股，第三大股东持有 5.7%。此外，首席执行官 Richard Miller 拥有公司 3.1% 的股份。</p>
</div><p>A closer look at our ownership figures suggests that the top 12 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.</p>
<div class="lb-trans"><p>更仔细地查看我们的所有权数据表明，前 12 大股东的合计持股比例为 51%，这意味着没有单一股东拥有多数股份。</p>
</div><p>While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.</p>
<div class="lb-trans"><p>虽然研究一家公司的机构持股可以为您的研究增值，但研究分析师的推荐也是一个好习惯，以更深入地了解股票的预期表现。有相当数量的分析师覆盖这只股票，因此了解他们对未来的整体看法可能会很有用。</p>
</div><h2>Insider Ownership Of Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 的内部持股</h2>
</div><p>While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.</p>
<div class="lb-trans"><p>虽然内部人的确切定义可能是主观的，但几乎所有人都认为董事会成员是内部人。公司管理层向董事会负责，而董事会应代表股东的利益。值得注意的是，有时高层管理人员本身也在董事会中。</p>
</div><p>Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.</p>
<div class="lb-trans"><p>大多数人认为内部持股是积极的，因为它可以表明董事会与其他股东的利益一致。然而，有时过多的权力集中在这个群体中。</p>
</div><p>We can report that insiders do own shares in Corvus Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$18m worth of the US$456m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.</p>
<div class="lb-trans"><p>我们可以报告，内部人确实持有 Corvus Pharmaceuticals, Inc. 的股份。作为个人，内部人共同持有价值 1800 万美元的公司股份，总市值为 4.56 亿美元。看到内部人进行一些投资是件好事，但可能值得检查这些内部人是否在增持。</p>
</div><h2>General Public Ownership</h2>
<div class="lb-trans"><h2>公众持股</h2>
</div><p>With a 40% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Corvus Pharmaceuticals. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.</p>
<div class="lb-trans"><p>公众持有 40% 的股份，主要由个人投资者组成，对 Corvus Pharmaceuticals 有一定的影响力。虽然这种持股规模可能不足以在政策决策中影响他们的利益，但他们仍然可以对公司政策产生集体影响。</p>
</div><h2>Private Equity Ownership</h2>
<div class="lb-trans"><h2>私募股权持股</h2>
</div><p>Private equity firms hold a 9.6% stake in Corvus Pharmaceuticals. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.</p>
<div class="lb-trans"><p>私募股权公司持有 Corvus Pharmaceuticals 9.6% 的股份。这表明他们在关键政策决策中可能具有影响力。有时我们看到私募股权公司会长期持有，但一般来说，他们的投资周期较短，正如其名所示，他们不太会投资于上市公司。经过一段时间，他们可能会考虑出售并将资本重新部署到其他地方。</p>
</div><h2>Next Steps:</h2>
<div class="lb-trans"><h2>下一步：</h2>
</div><p>It's always worth thinking about the different groups who own shares in a company. But to understand Corvus Pharmaceuticals better, we need to consider many other factors. Take risks for example - Corvus Pharmaceuticals has <strong>3 warning signs</strong> (and 1 which is significant) we think you should know about.</p>
<div class="lb-trans"><p>考虑拥有公司股份的不同群体总是值得的。但要更好地理解 Corvus Pharmaceuticals，我们需要考虑许多其他因素。例如，风险 - Corvus Pharmaceuticals 有 <strong>3 个警告信号</strong>（其中 1 个是显著的），我们认为您应该了解。</p>
</div><p>But ultimately <strong>it is the future</strong>, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.</p>
<div class="lb-trans"><p>但最终 <strong>未来</strong> 而不是过去，将决定这家公司的所有者将如何表现。因此，我们认为查看这份免费的报告是明智的，该报告显示分析师是否预测更光明的未来。</p>
</div><p>NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.</p>
<div class="lb-trans"><p>注意：本文中的数据是根据过去 12 个月的数据计算得出的，指的是财务报表日期所在月份的最后一天结束的 12 个月期间。这可能与全年年报数据不一致。</p>
</div>

While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most

尽管机构投资者从上周 Corvus 制药公司（NASDAQ:CRVS）12% 的涨幅中受益，但个人投资者的收益最大